For advertising opportunities or to purchase this domain, please contact [email protected]
Retatrutide
The GLP-3 frontier
Eli Lilly's next-generation obesity and metabolic therapy targets three hormone receptors simultaneously — GIP, GLP-1, and glucagon — delivering weight loss results that exceed everything that came before it.
Three receptors.
One molecule.
Retatrutide is a single engineered peptide that simultaneously activates the body's GIP, GLP-1, and glucagon receptors — a design that creates synergistic effects no single-target drug can match.
GIP Receptor
Glucose-dependent insulinotropic polypeptide (GIP) enhances insulin secretion, improves insulin sensitivity, and promotes fat storage regulation. Retatrutide shows higher potency at the human GIP receptor than natural GIP itself, amplifying its metabolic effects.
Incretin hormoneGLP-1 Receptor
Glucagon-like peptide-1 (GLP-1) slows gastric emptying, suppresses appetite signals in the brain, and stimulates insulin release. This is the same pathway targeted by semaglutide (Ozempic/Wegovy) — the proven anchor of modern obesity pharmacotherapy.
Appetite regulationGlucagon Receptor
The addition of glucagon receptor agonism — absent in all predecessors — boosts energy expenditure and enhances fatty acid oxidation, accelerating fat burning beyond what GIP and GLP-1 alone can achieve. This third axis is the key differentiator.
Energy expenditurePrevious generation drugs
- Semaglutide (GLP-1 only)
- Liraglutide (GLP-1 only)
- Tirzepatide (GIP + GLP-1)
- Single or dual receptor targets
- Limited energy expenditure boost
Retatrutide (GIP + GLP-1 + Glucagon)
- Triple receptor activation
- Enhanced fatty acid oxidation
- Greater energy expenditure
- Superior weight loss vs. predecessors
- Pain reduction in osteoarthritis
What the trials show
Phase 2 and Phase 3 results establish retatrutide as the most potent weight loss pharmacotherapy ever tested in large-scale randomized controlled trials.
Weight loss vs. comparators
TRIUMPH-4 trial design
Phase 3, 68-week, randomized, double-blind, placebo-controlled. 445 participants (1:1:1 ratio — 9 mg, 12 mg, or placebo). Adults with obesity/overweight and knee osteoarthritis, without diabetes. Step-wise dose escalation from 2 mg.
Side effect profile (12 mg vs. placebo)
Notable finding: The discontinuation rate due to adverse events (18.2% at 12 mg) is roughly three times higher than tirzepatide's 6.2%. Some discontinuations were specifically due to perceived excessive weight loss — an unusual challenge that may inform flexible dosing strategies in practice.
Glycemic benefit: Across Phase 2 trials, participants saw a 1.7–2.0% reduction in HbA1c — a meaningful improvement in blood sugar control alongside the weight loss effects.
The TRIUMPH program
Lilly is running multiple Phase 3 trials across a broad range of obesity-related conditions under the TRIUMPH (TRIple hormone receptor agOnist for oUtcoMes in obestiy and cardiometabolic Programs and Health) program.
Obesity / Overweight
Primary indication. Adults with BMI ≥27 with at least one weight-related comorbidity, or BMI ≥30.
Phase 3 activeType 2 Diabetes
Dedicated Phase 3 trials evaluating glycemic control and weight loss in T2D populations.
Phase 3Knee Osteoarthritis
TRIUMPH-4 success: 28.7% weight loss and 75.8% pain score reduction. First positive Phase 3 readout.
Phase 3 positiveObstructive Sleep Apnea
Moderate-to-severe OSA trial evaluating whether metabolic improvement reduces apnea events.
Phase 3Cardiovascular & Renal Outcomes
Long-term outcomes trial assessing MACE reduction and kidney protection in high-risk patients.
Phase 3Chronic Low Back Pain
Evaluating whether significant weight reduction translates to measurable pain relief in CLBP.
Phase 3Metabolic Liver Disease (MASLD)
Metabolic dysfunction-associated steatotic liver disease — testing hepatic fat reduction.
Phase 3From lab to pharmacy
Retatrutide has moved quickly through development. Here is the key milestones and what lies ahead.
First-in-human studies
Single-dose studies in healthy subjects confirm tolerability and significant effects on appetite regulation and early weight loss signals. Prolonged pharmacokinetic half-life established.
Phase 2 results — landmark efficacy
40-week Phase 2 trial reports up to 24% weight loss and a 1.7–2.0% drop in HbA1c at 12 mg. Results published; expert consensus describes the data as "very solid." TRIUMPH Phase 3 program launched.
TRIUMPH-4 — first Phase 3 success
28.7% average weight loss and 75.8% pain reduction in obesity + knee osteoarthritis trial. Beats analysts' bull-case projections. Retatrutide surpasses tirzepatide's efficacy benchmark.
Additional TRIUMPH Phase 3 readouts
Seven more trials expected to report, including obesity without comorbidities, type 2 diabetes, and the 4 mg maintenance dose cohort. Full regulatory submission preparation likely begins.
Potential FDA approval
GlobalData forecasts a 2027 FDA approval — contingent on successful remaining Phase 3 readouts and submission acceptance. Lilly is already manufacturing at scale.
$15.6 billion sales forecast
GlobalData's patient-based forecast projects retatrutide reaching $15.6B in annual sales by 2031 — potentially surpassing tirzepatide's $3.6B quarterly run rate within a few years of launch.
How it stacks up
A side-by-side look at retatrutide against current approved and emerging obesity therapies.
| Drug | Targets | Best weight loss | Dosing | Status |
|---|---|---|---|---|
| RetatrutideEli Lilly · LY3437943 | GIP GLP-1 Glucagon | 28.7% at 68 wk (12 mg) | Weekly injection | Phase 3 |
| Tirzepatide (Zepbound)Eli Lilly · dual agonist | GIP GLP-1 | 22.5% at 72 wk (15 mg) | Weekly injection | FDA Approved |
| Semaglutide (Wegovy)Novo Nordisk | GLP-1 | ~15% at 68 wk (2.4 mg) | Weekly injection | FDA Approved |
| Oral semaglutide (Rybelsus)Novo Nordisk | GLP-1 | ~5% (T2D approved form) | Daily pill | Approved (T2D) |
| OrforglipronEli Lilly · oral GLP-1 | GLP-1 | Phase 3 success reported | Daily pill | Awaiting FDA |
| Cagrilintide + semaglutideNovo Nordisk · CagriSema | GLP-1 Amylin | ~22.7% at 68 wk | Weekly injection | Phase 3 |
Comparisons are approximate and drawn from different trial populations and durations. Direct head-to-head data does not currently exist.
Andrew Huberman on retatrutide
No single voice has done more to bring retatrutide into mainstream awareness than Stanford neurobiologist Andrew Huberman. Here are his key discussions and where to find them.
"Retatrutide is the peptide that's going to change everything. People can lose up to a third of their body weight over a year or so."
Huberman has described retatrutide as "probably the biggest thing to hit the health space in the last 10 years." He has been transparent that he has not personally used GLP-1 agonists, writing on X: "I've not tried GLP-1 agonists. If I ever do I will say."
He has also observed that celebrity use already appears widespread, noting: "Not a week goes by where I don't get 100 questions about Retatrutide to my phone, my personal phone, let alone email." After his commentary went viral, he issued multiple public statements denying any financial ties to pharmaceutical or peptide companies.
Dr. Zachary Knight: The Science of Hunger & Medications to Combat Obesity
Huberman and UCSF physiology professor Dr. Zachary Knight cover how GLP-1, GIP, and the hunger-regulating brain circuits work — and explicitly reference LY3437943 (retatrutide) as the next-generation triple agonist in their show notes. The deep scientific foundation for understanding retatrutide's design.
Listen on Huberman Lab ↗Dr. Craig Koniver: Peptide & Hormone Therapies for Health, Performance & Longevity
A comprehensive episode on the peptide landscape featuring GLP-1 analogs, microdosing strategies, and how to offset muscle loss. Koniver and Huberman discuss how compounding pharmacy access changed the conversation around GLP-1 therapies, and the road toward retatrutide.
Listen on Huberman Lab ↗Andrew Huberman — JRE #2195
Huberman's most recent full appearance on JRE. The two cover peptides, GLP-1 agonists, performance enhancement, and the bodybuilding-to-Hollywood-to-mainstream pipeline that Huberman believes retatrutide will follow. A significant portion of the conversation addresses the future of metabolic pharmacotherapy.
Listen on Apple Podcasts ↗Peptide Stacking, GLP-1s, and the Gila Monster That Changed Weight Loss
Huberman explains the full origin story of GLP-1 (traced to Gila monster venom), the shift from single to triple agonists, and why retatrutide specifically hits three pathways "each a bit more subtly." He also warns against black-market sources: "If you want true, pure retatrutide, you'll have to get it from Eli Lilly."
Read & listen on Goop ↗"All the celebs now getting that retatrutide look"
A series of posts in early 2026 brought Huberman's retatrutide commentary to millions. He predicted it would follow the same path as every performance drug since the 1980s: "It always goes from bodybuilding → Hollywood → mainstream. EVERY TIME." He later denied any financial conflicts after audience backlash.
Read coverage ↗Andrew Huberman — Club Random with Bill Maher
Huberman joins Bill Maher on his freewheeling Club Random podcast. The conversation covers biohacking, peptides, and Big Pharma incentives — with Huberman digging into the GLP landscape and retatrutide specifically. Maher probes what's real versus hype in the wellness space. The retatrutide discussion begins around the 47-minute mark. Also available on Apple Podcasts and Spotify.
Watch on YouTube (from timestamp) ↗Peptides, Sleep Tech & the End of Obesity
In conversation with Andreessen Horowitz's Daisy Wolf, Huberman covers the emerging peptide and GLP landscape and frames retatrutide within a broader consumer health revolution. He also predicts that neurotechnologies will let us "write to our own biology" within five years — with metabolic peptides as the first chapter.
Listen on Apple Podcasts ↗Huberman Forced to Deny Conflict of Interest Over Peptide Commentary
As Huberman's retatrutide enthusiasm intensified, scrutiny followed. This piece covers his public denials, the audience skepticism on Reddit and X, and the broader debate about whether wellness influencers should predict specific drugs. Huberman's statement: "I'm not paid by any pharma company or peptide company."
Read article ↗